About Journey Medical Corporation
https://journeymedicalcorp.comJourney Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
CEO
Claude Maraoui
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:1.85M
Value:$14.54M
WASATCH ADVISORS LP
Shares:1.31M
Value:$10.24M
OPALEYE MANAGEMENT INC.
Shares:971.06K
Value:$7.61M
Summary
Showing Top 3 of 74
About Journey Medical Corporation
https://journeymedicalcorp.comJourney Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $17.63M ▲ | $13.4M ▲ | $-2.31M ▲ | -13.13% ▲ | $-0.09 ▲ | $-314K ▲ |
| Q2-2025 | $15.01M ▲ | $11.88M ▲ | $-3.8M ▲ | -25.29% ▲ | $-0.16 ▲ | $-1.71M ▲ |
| Q1-2025 | $13.14M ▼ | $11.67M ▲ | $-4.07M ▼ | -31% ▼ | $-0.18 ▼ | $-2.1M ▼ |
| Q4-2024 | $13.62M ▼ | $9.15M ▼ | $1.52M ▲ | 11.17% ▲ | $0.07 ▲ | $3.42M ▲ |
| Q3-2024 | $14.63M | $12.24M | $-2.39M | -16.34% | $-0.12 | $-795K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $24.95M ▲ | $85.19M ▲ | $59.29M ▼ | $25.9M ▲ |
| Q2-2025 | $20.29M ▼ | $81.16M ▼ | $61.91M ▼ | $19.25M ▼ |
| Q1-2025 | $21.07M ▲ | $84.96M ▲ | $63.42M ▲ | $21.54M ▲ |
| Q4-2024 | $20.3M ▼ | $80.24M ▲ | $60.17M ▲ | $20.07M ▲ |
| Q3-2024 | $22.46M | $64.04M | $53.12M | $10.93M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-3.8M ▲ | $-942K ▲ | $0 | $165K ▼ | $-777K ▼ | $-942K ▲ |
| Q1-2025 | $-4.07M ▼ | $-2.83M ▼ | $0 ▲ | $3.6M ▼ | $765K ▲ | $-2.83M ▼ |
| Q4-2024 | $1.52M ▲ | $2.23M ▲ | $-15M ▼ | $10.62M ▲ | $-2.16M ▼ | $2.23M ▲ |
| Q3-2024 | $-2.39M ▲ | $-1.16M ▲ | $0 | $-294K ▼ | $-1.45M ▼ | $-1.16M ▲ |
| Q2-2024 | $-3.36M | $-5.18M | $0 | $5.03M | $-145K | $-5.18M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Accutane | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Amzeeq | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Qbrexza | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Zilxi | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Claude Maraoui
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:1.85M
Value:$14.54M
WASATCH ADVISORS LP
Shares:1.31M
Value:$10.24M
OPALEYE MANAGEMENT INC.
Shares:971.06K
Value:$7.61M
Summary
Showing Top 3 of 74